- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03808519
n3 PUFA and Muscle-disuse Atrophy in Older Women
Effects of n3 PUFA Supplementation on the Attenuation of Muscle Disuse Atrophy in Older Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. More importantly, older adults (especially older women) that experience periods of muscle disuse are unable to recover muscle mass and strength. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.
Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. A previous study from our group demonstrated that younger women supplementing with n3 PUFA-enriched fish oil attenuated declines in skeletal muscle mass and strength during 2 weeks of immobilization. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization in older women.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- Exercise Metabolism Research Laboratory, McMaster Univeristy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Aged 55 - 75 years old
- non-smoking (for at least 2 years)
- > 5 years post-menopausal
- Body mass index (BMI) between 22 and 33 kg/m2
- Mini-Mental State Exam (MMSE) score > 20
- Acceptable medications include: Angiotensin Converting Enzyme (ACE), Beta-Blockers, Acetylsalicylic Acid, Calcium Channel blockers, Depression/Anxiety meds, Bisphosphonates (Fosamax®, Didrocal®, Actonel®, Aclasta®).
Exclusion Criteria:
- Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigators, would compromise the ability to comply with the study requirements.
- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression over the past 2 years.
- Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude oral n-3 PUFA supplement ingestion and/or assessment of safety and study objectives
- Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing)
- Participation in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study
- Hypersensitivity to the test product
- Excessive alcohol consumption (>21 units/week)
- Prior gastrointestinal bypass surgery
- History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy
- Personal or family history of clotting disorder or deep vein thrombosis
- Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), or any anabolic steroid
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: n3 PUFA
n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
|
3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
|
PLACEBO_COMPARATOR: Placebo
Organic Sunflower Oil 5000mg per day
|
Organic Sunflower Oil 5000mg per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle Cross-Sectional Area
Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Changes in muscle cross-sectional area assessed by ultrasonography
|
Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Integrated rates of muscle protein synthesis
Time Frame: pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Change in muscle protein synthesis using doubly labelled water (D2O)
|
pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Skeletal muscle strength
Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Change in skeletal muscle strength using the Biodex Dynamometer
|
Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Endothelial function
Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Change in flow-mediated dilation
|
Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Vascular function
Time Frame: Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Change in total femoral flow
|
Baseline (-28 days), pre-immobilization (0 days), post-immobilization (7 days), recovery (21 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HiREB 1932
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on n3 PUFA-enriched fish oil
-
McMaster UniversityUniversity of GuelphCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedProteomics | Lipoprotein Metabolism | PCSK9United States
-
The Adelaide and Meath HospitalUniversity College DublinCompletedPolycystic Ovary SyndromeIreland
-
The Adelaide and Meath HospitalUniversity College DublinCompletedPolycystic Ovary SyndromeIreland
-
Peking Union Medical College HospitalNot yet recruiting
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)UnknownEndothelial Dysfunction | Vascular Dementia | Executive Dysfunction | Alzheimer's Disease | Age Related Cognitive DeclineUnited States
-
Loughborough UniversityCompletedExercise-induced InflammationUnited Kingdom
-
Loughborough UniversityUniversity of WorcesterCompletedExercise-induced Inflammation
-
University of CopenhagenDanish Research Agency; Technical University of Denmark; HjerteforeningenUnknownMetabolic Syndrome | Cardiovascular Heart DiseaseDenmark
-
University of ManitobaCanadian Institutes of Health Research (CIHR)CompletedInflammation | ObesityCanada